Cargando…
53. TUCATINIB VS PLACEBO ADDED TO TRASTUZUMAB AND CAPECITABINE FOR PATIENTS WITH PREVIOUSLY TREATED HER2+ METASTATIC BREAST CANCER (MBC) WITH BRAIN METASTASES (BM) (HER2CLIMB)
BACKGROUND: HER2CLIMB (NCT02614794) primary results have been reported previously (Murthy, NEJM 2019). We report results of exploratory efficacy analyses in pts with brain metastases (BM). METHODS: All HER2+ MBC pts enrolled had a baseline brain MRI. Pts with BM were eligible and randomized 2:1 to r...
Autores principales: | Lin, Nancy, Murthy, Rashmi, Anders, Carey, Borges, Virginia, Hurvitz, Sara, Loi, Sherene, Abramson, Vandana, Bedard, Philippe, Oliveira, Mafalda, Zelnack, Amelia, DiGiovanna, Michael, Bachelot, Thomas, Chien, A Jo, O’Regan, Ruth, Wardley, Andrew, Mueller, Volkmar, Carey, Lisa, McGoldrick, Suzanne, An, Xuebei, Winer, Eric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7401403/ http://dx.doi.org/10.1093/noajnl/vdaa073.041 |
Ejemplares similares
-
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
por: Lin, Nancy U., et al.
Publicado: (2020) -
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial
por: Lin, Nancy U., et al.
Publicado: (2022) -
The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer
por: Sirhan, Zaid, et al.
Publicado: (2022) -
Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry
por: Gampenrieder, Simon Peter, et al.
Publicado: (2021) -
Real-world patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer
por: Kaufman, Peter A., et al.
Publicado: (2023)